Streetbeat News

Products Services

INDP

Indaptus Therapeutics has successfully advanced its Phase 1 trial for Decoy20, a novel immuno-oncology therapy targeting advanced solid tumors. The trial confirmed the 'Pulse-Prime' hypothesis and identified a tolerable single dose for multi-dosing, which will be presented at ASCO.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2024 | 12:16 pm

BIVI

BioVie announced that its Phase 2a trial for bezisterim in Parkinson's Disease showed significant improvements in both non-motor and motor symptoms for treated patients, while placebo-treated patients worsened.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2024 | 12:14 pm

ANL

Adlai Nortye has dosed the first patient in a randomized Phase II clinical trial of Palupiprant for the treatment of locally advanced rectal cancer in combination with radiation therapy.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2024 | 12:13 pm

AVDL

Avadel Pharmaceuticals (NASDAQ: AVDL) will present new data on LUMRYZ, an extended-release oral suspension for narcolepsy, at SLEEP 2024. The company will showcase 11 posters and one oral presentation, highlighting the clinical benefits and patient satisfaction with LUMRYZ.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2024 | 12:13 pm

MA

SYF

Virgin Red has partnered with Synchrony and Mastercard to launch the Virgin Red Rewards World Elite Mastercard credit card program in the U.S. Synchrony will be the exclusive issuer, and Mastercard will be the exclusive payments network. The card will offer various perks and rewards, including boosting Virgin Points.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2024 | 12:11 pm

AIXI

Xiao-I Corporation has announced a partnership with a major Chinese bank to implement an intelligent customer service training system called 'Smart Coach,' which utilizes advanced AI solutions to enhance customer service training.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2024 | 12:10 pm

BRNS

Barinthus Bio will present updates on its lead hepatitis B asset, VTP-300, at the EASL Congress 2024. The presentations will include more mature interim data, potentially indicating rates of functional cure.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2024 | 12:09 pm

LEGN

MXCT

MaxCyte has signed a license agreement with Legend Biotech, granting Legend a non-exclusive worldwide license to use MaxCyte's Flow Electroporation and ExPERT platform. MaxCyte will be eligible for fees and milestones.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2024 | 12:08 pm

SLNH

Soluna Holdings, Inc. (NASDAQ: SLNH) has signed a Power Purchase Agreement (PPA) with EDF Renewables and Masdar for Project Kati, aiming to expand its portfolio and unlock 166 MW of hosting potential. This marks a significant milestone in the company's growth.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2024 | 12:08 pm

ESPR

The European Commission has approved NILEMDO (bempedoic acid) and its combination with ezetimibe, NUSTENDI, for treating hypercholesterolemia and reducing cardiovascular risk. This approval makes bempedoic acid the first and only LDL-C lowering treatment indicated for primary and secondary prevention of cardiovascular events.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2024 | 12:08 pm